image

Investors

Corporate Profile

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Filing date Description Form View

A statement of beneficial ownership of common stock by certain persons

SC 13G View HTML

An amendment to the SC 13G filing

SC 13G/A View HTML

An amendment to the SC 13G filing

SC 13G/A View HTML

Report of unscheduled material events or corporate event

8-K EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML

Statement of changes in beneficial ownership of securities

4 View HTML

Statement of changes in beneficial ownership of securities

4 View HTML

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

144 View HTML

Report of unscheduled material events or corporate event

8-K EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML

Report of unscheduled material events or corporate event

8-K EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML

Report of unscheduled material events or corporate event

8-K EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML

Data provided by Kaleidoscope.